Nanopores follow nature's lead in tracking proteins
Presented in the journal Nature Nanotechnology, the study was partially supported by the EU-funded NANOSCI-EPLUS and READNA projects.
Biomimetics is the scientific field whereby human-made processes, substances, devices, or systems imitate nature. In their study, the researchers introduce an artificial nanopore that works together with key proteins mimicking the natural nuclear pore. This innovation enables a new and powerful platform to keep track of how single proteins move.
Investigating how individual proteins move through the biomimetic pore, the Delft University of Technology (TU Delft, the Netherlands) and the University of Basel (Switzerland) scientists discovered that the majority of proteins fail to move through while a number of specific proteins succeed. According to the team, the biomimetic pore functions properly and researchers can use it as a testing platform to determine how drugs are delivered into a cell's nucleus.
'Human cells have a nucleus, and proteins and RNA [ribonucleic acid] need to get in and out,' explains Professor Cees Dekker, head of TU Delft's Kavli Institute of Nanoscience and research leader. 'This is regulated by small holes, called nuclear pore complexes. These are essential biological pores that act as gatekeepers of the cell nucleus. They transport proteins and RNA in and out of the nucleus in a highly selective manner, which means that some go through but others are blocked from passing,' he adds.
'There is much debate on how this intriguing selectivity is achieved. Given the fact that it is very difficult to perform high-resolution measurements in the complex environment of the living cell, the exact mechanism is hard to resolve.'
Professor Dekker says biomimetics is a promising approach for studying this nuclear transport. 'Advances in nanotechnology now make it possible to study and shape matter at the nanometre scale, opening the way to imitate biological structures at the molecular level to both study and harness their ingenuity,' he points out.
The Dekker group produced the biomimetic nanopores by attaching the proteins to small holes in a solid-state support, while his colleague, Basel's Dr Roderick Lim and his team purified the nuclear pore proteins.
NANOSCI-EPLUS ('Transnational call for collaborative proposals in basic nanoscience research') has clinched an ERA-NET Plus in Nanosciences grant worth more than EUR 6.3 million under the EU's Seventh Framework Programme (FP7). Led by the French-based institution Centre National de la Recherche Scientifique (CNRS), the NANOSCI-EPLUS project brings together experts from Austria, Finland, France, Germany, Ireland, Israel, Italy, the Netherlands, Poland, Portugal, Slovakia, Spain and the United Kingdom.
READNA ('Revolutionary approaches and devices for nucleic acid analysis') is funded under the Health Theme of FP7 to the tune of almost EUR 12 million and brings together business and research experts from Denmark, Germany, France, the Netherlands, Sweden and the United Kingdom.
For more information, please visit:
Delft University of Technology:
ERA-NET Plus projects:
Health Research in FP7:
Source: Cordis /...
Previous Story: Many eager to use nano in food, but few ready to admit it
Next Story: Rare razor set to cut a dapper dash
The Institute of Nanotechnology puts significant effort into ensuring that the information provided on its news pages is accurate and up-to-date. However, we cannot guarantee absolute accuracy. Consequently, the Institute of Nanotechnology disclaims any and all responsibility for inaccuracy, omission or any kind of deficiency in relation to the news items and articles hosted herein.
- 29 July 2014Nanotechnology and tyres: Greening industry and transport
- 22 July 2014Supporting Recommendations for Future Topics in Horizon 2020
- 17 June 20142014 edition of European NanoSafety Cluster Compendium now online
- 14 May 2014Gold nanoparticles for cancer treatment
- 22 April 2014Irish Materials Research Centre (AMBER) in World First Graphene Innovation
- View All